Details of the Optogenetic System
General Information of This Optogenetic System (OS) | ||||||
---|---|---|---|---|---|---|
OS ID |
OS00278
|
|||||
OS Name |
Tamoxifen-gated photoactivatable split-Cre recombinase optogenetic system
(TamPA-Cre)
|
[1] | ||||
Photoreceptor (PR) |
||||||
Complementary Protein | Positive Magnet (pMag) | |||||
Cofactor | Flavin adenine dinucleotide (FAD) | |||||
Controlled Protein | Fusion protein | CreN means N terminal of Cre recombinase and CreC means C terminal of Cre recombinase | ||||
Estrogen receptor ligand binding domain ERT2 | ||||||
Recruited protein | CreN means N terminal of Cre recombinase and CreC means C terminal of Cre recombinase | |||||
OS Application Information (1) | ||||||
---|---|---|---|---|---|---|
Mechanism of Action | nMag-pMag heterodimerization | [ 1] | ||||
Controlled Signal Pathway | Tamoxifen dependent gene activation | |||||
Effect | Activation | |||||
Application | Specifically control localized CAR expression and subsequently T cell activation | |||||
Note | Tamoxifen (500 nM) needed at the same time to activate the switch | |||||
Light Information | Activation Wavelength | 473 ± 29 nm | ||||
Process | Reversible | |||||
Deactivation Wavelength | Dark | |||||
Activation Time | Seconds | |||||
Deactivation Time | Seconds to Minutes | |||||
Light Intensity | 5 watts per square meter | |||||
Expression Information | Expression Method | Transduction and Transfection | ||||
Cell Lines | CAR reporter jurkat T cells lines and HEK293T cells | |||||